MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
NCT05090566
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This study is trying to find out how much of a new drug called elranatamab, when given with other cancer drugs, helps people with a type of cancer called multiple myeloma. They want to know what the right amount of this new drug is and how it helps people.
This study is trying to find out how much of a new drug called elranatamab, when given with other cancer drugs, helps people with a type of cancer called multiple myeloma. They want to know what the right amount of this new drug is and how it helps people.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.
The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
